Clinical Trial Update: DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the effects of DAPAgliflozin on water balance in patients at high cardiovascular risk; status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Risk Factors

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Cardiovascular Risk Factor | Phase 2 | Status: UNKNOWN